Clearmind Medicine Inc. (NASDAQ: CMND), a clinical-stage biopharmaceutical company developing non-hallucinogenic, psychedelic-derived neuroplastogens, announced on October 7, 2026 that it submitted recommendations to the U.S….
Key Points Psyence BioMed’s Texas subsidiary, TIRC, signed a manufacturing agreement with Benuvia Operations for planned U.S. production of pharmaceutical-grade ibogaine API. Benuvia operates an…
Key Points TIRC and PsyLabs aim to sign a definitive agreement by November 30, 2026. If they do not, the binding term sheet will lapse….
Clearmind Medicine Presents Non-Hallucinogenic Psychedelic Research at FDA Hearing
Key Points Clearmind Medicine’s Chief of Global Impact, Mary-Elizabeth Gifford, testified at the FDA’s September 14 hearing on the potential future therapeutic use of psychedelic…
Key Points Definium Therapeutics said its Phase 3 Panorama trial met its main goal and all key secondary efficacy endpoints in adults with generalized anxiety…
Key Points Compass Pathways was named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech, and Fierce Healthcare. The recognition highlights organizations and…
Numinus Wellness Reports 29% Quarterly Revenue Growth as Practitioner Training Accelerates
Key Points Q4 fiscal 2025 revenue increased 29% sequentially to C$2.33 million. Gross profit rose 63.5% from the prior quarter to C$1.42 million. Gross margin…
Key Points Definium Therapeutics reported positive Phase 3 results for DT120, its investigational LSD-based treatment for generalized anxiety disorder, or GAD. A single DT120 dose…
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA), a clinical-stage pharmaceutical company developing oral small-molecule therapeutics for neurologic, inflammatory, metabolic, and neuropsychiatric disorders, announced on July 30, 2026…
AtaiBeckley Inc. (NASDAQ: ATAI) is ripping higher today, up about 33% to 7.125, after Eli Lilly announced a deal to acquire the company. Lilly is…
AtaiBeckley just had a breakout moment, with its share price soaring on news that Eli Lilly is in talks to buy the psychedelic drug developer….
BlackBerry Limited (NYSE: BB) is putting in a strong session today, with the stock up about 20% to 10.37 from a prior close of 8.62….





